Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last
decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin …

Pulmonary hypertension (PH) is a deadly vascular disease with enigmatic molecular origins.
We found that vascular extracellular matrix (ECM) remodeling and stiffening are early and …

Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary
pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic …

Background—We previously reported high-throughput RNA sequencing analyses that
identified heightened expression of the chromatin architectural factor High Mobility Group AT …

In familial pulmonary arterial hypertension (FPAH), the autosomal dominant disease-
causing BMPR2 mutation is only 20% penetrant, suggesting that genetic variation provides …

Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary dysfunctional disease,
characterized by progressive vascular remodeling. Inflammation is an increasingly …

Arteriovenous malformations are a vascular anomaly typically present at birth, characterized
by an abnormal connection between an artery and a vein (bypassing the capillaries). These …

The vascular system is critical for developmental growth, tissue homeostasis and repair but
also for tumor development. Bone morphogenetic protein (BMP) signaling has recently …

Recent studies have focused on the contribution of capillary endothelial TRPV4 channels to
pulmonary pathologies, including lung edema and lung injury. However, in pulmonary …

Apelin and its G protein-coupled receptor (GPCR) have emerged as a key signalling
pathway in the cardiovascular system. The peptide is a potent inotropic agent and …